The Treatment Resistant Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Treatment Resistant Depression Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treatment Resistant Depression Market.
Some of the key takeaways from the Treatment Resistant Depression Pipeline Report:
- Companies across the globe are diligently working toward developing novel Treatment Resistant Depression treatment therapies with a considerable amount of success over the years.
- Treatment Resistant Depression companies working in the treatment market are Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others, are developing therapies for the Treatment Resistant Depression treatment
- Emerging Treatment Resistant Depression therapies in the different phases of clinical trials are- Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others are expected to have a significant impact on the Treatment Resistant Depression market in the coming years.
- In January 2023, A Phase III, multicenter, randomized, double-blind, placebo-controlled trial was started by COMPASS Pathways to look into the safety, tolerability, and effectiveness of giving COMP360 once to those who have treatment-resistant depression.
- In February 2023, A Phase III, multicenter, randomized, double-blind, controlled trial was started by COMPASS Pathways to look into the safety, effectiveness, and tolerability of two COMP360 administrations in individuals with treatment-resistant depression.
- In January 2020, The US Patent and Trademark Office awarded COMPASS Pathways US Patent No. 10,519,175 for its psilocybin-based treatment techniques for drug-resistant depression. The application of COMP360, an experimental psilocybin formulation manufactured by COMPASS, in a psilocybin therapy regimen for patients with treatment-resistant depression is covered by the patent.
Treatment Resistant Depression Overview
When two or more antidepressants are taken for a sufficient amount of time at a sufficient dose and with sufficient confirmation of treatment adherence, treatment-resistant depression (TRD) is generally defined as an unsatisfactory response to at least two of them. In clinical practice, TRD is a quite typical occurrence, with up to 50–60% of patients not seeing a sufficient response after antidepressant medication.
Get a Free Sample PDF Report to know more about Treatment Resistant Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight
Emerging Treatment Resistant Depression Drugs Under Different Phases of Clinical Development Include:
- Ebselen: Sound Pharmaceuticals
- HS-10345: Jiangsu Hansoh Pharmaceutical
- MK-1942: Merck Sharp & Dohme
- MIJ821: Novartis
- Liafensine: Denovo Biopharma LLC
- Psilocybin: COMPASS Pathways
- NV5138: Navitor Pharmaceuticals/Supernus Pharmaceuticals
- REL-1017: Relmada Therapeutics
- BPL-003: Beckley Psytech
- COMP360 (Psilocybin): COMPASS Pathways
- AXS-05: Axsome Therapeutics
- FALKIERI (esketamine DPI): Celon Pharma
Treatment Resistant Depression Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Treatment Resistant Depression Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Treatment Resistant Depression Pipeline Therapeutics Assessment
- Treatment Resistant Depression Assessment by Product Type
- Treatment Resistant Depression By Stage and Product Type
- Treatment Resistant Depression Assessment by Route of Administration
- Treatment Resistant Depression By Stage and Route of Administration
- Treatment Resistant Depression Assessment by Molecule Type
- Treatment Resistant Depression by Stage and Molecule Type
DelveInsight’s Treatment Resistant Depression Report covers around 25+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Treatment Resistant Depression product details are provided in the report. Download the Treatment Resistant Depression pipeline report to learn more about the emerging Treatment Resistant Depression therapies
Some of the key companies in the Treatment Resistant Depression Therapeutics Market include:
Key companies developing therapies for Treatment Resistant Depression are – Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
Treatment Resistant Depression Pipeline Analysis:
The Treatment Resistant Depression pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Treatment Resistant Depression with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treatment Resistant Depression Treatment.
- Treatment Resistant Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Treatment Resistant Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treatment Resistant Depression market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Treatment Resistant Depression drugs and therapies
Treatment Resistant Depression Pipeline Market Drivers
- Increasing Prevalence of Treatment Resistant Depression, increase in Research and Developmental activities for the treatment of Treatment Resistant Depression are some of the important factors that are fueling the Treatment Resistant Depression Market.
Treatment Resistant Depression Pipeline Market Barriers
- However, side-effects associated with the treatment of Treatment Resistant Depression • Poor management of Treatment Resistant Depression and other factors are creating obstacles in the Treatment Resistant Depression Market growth.
Scope of Treatment Resistant Depression Pipeline Drug Insight
- Coverage: Global
- Key Treatment Resistant Depression Companies: Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others
- Key Treatment Resistant Depression Therapies: Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others
- Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
- Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers
Request for Sample PDF Report for Treatment Resistant Depression Pipeline Assessment and clinical trials
Table of Contents
1. Treatment Resistant Depression Report Introduction
2. Treatment Resistant Depression Executive Summary
3. Treatment Resistant Depression Overview
4. Treatment Resistant Depression- Analytical Perspective In-depth Commercial Assessment
5. Treatment Resistant Depression Pipeline Therapeutics
6. Treatment Resistant Depression Late Stage Products (Phase II/III)
7. Treatment Resistant Depression Mid Stage Products (Phase II)
8. Treatment Resistant Depression Early Stage Products (Phase I)
9. Treatment Resistant Depression Preclinical Stage Products
10. Treatment Resistant Depression Therapeutics Assessment
11. Treatment Resistant Depression Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Treatment Resistant Depression Key Companies
14. Treatment Resistant Depression Key Products
15. Treatment Resistant Depression Unmet Needs
16 . Treatment Resistant Depression Market Drivers and Barriers
17. Treatment Resistant Depression Future Perspectives and Conclusion
18. Treatment Resistant Depression Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services